Two Sustained Release Membranes Used in Formulating Low Strength
Testosterone Reservoir Transdermal Patches

Ria      Vashishth; Monica   C.   Chuong; Juan   Chang   Duarte; Yadnya      Gharat; Stephen   G.   Kerr

doi:10.2174/1567201820666230316115921

Abstract

Introduction: Several Testosterone Replacement Therapies exist for hypogonadism, but an in-depth analysis of these products reveals a high dosing frequency and a high drug loading, up to 120 mg for a potent drug like Testosterone. This may lead to patient non-compliance and toxicity problems if used improperly. Androderm^® is the only 24-hour marketed transdermal patch. Testopel pellets are another extended-release product given subcutaneously every 3-6 months. But it requires surgical implantation and is associated with severe adverse effects. For this reason, the development of other extended- release testosterone products is needed. The study aims at using different excipients for the exploration of sustained-release patches.

Methods: Reservoir formulations were prepared using Carbomer 941 and HPMC K100M as the sustained- release polymers plus CoTran™ 9702 and CoTran™ 9712 as the release membranes. The formulated patches were subjected to in vitro dissolution for 24 h. The amount of drug release at each time point was determined using the developed HPLC assay. FDA Similarity Factor, f₂, t-test, and ANOVA were applied to all nine-point collected samples.

Results: CoTran™ 9712 membrane was found to be a better candidate than CoTran™ 9702. The in vitro release profiles of the four formulations were compared (Carbomer vs. HPMC, and CoTran™ 9702 vs. CoTran™ 9712).

Conclusion: CoTran™ 9702 releases testosterone significantly lower. Carbomer and CoTran™ 9712 were the best formulation among all with the highest drug release of 2.16 ± 0.36 mg.

« Previous Next »

Graphical Abstract

[1]
Ghosh, T.K. Dermal drug delivery: from innovation to production, 1st ed; CRC, 2019. 

[2]
Qaseem, A.; Horwitch, C.A.; Vijan, S.; Etxeandia-Ikobaltzeta, I.; Kansagara, D.; Forciea, M.A.; Crandall, C.; Fitterman, N.; Hicks, L.A.; Lin, J.S.; Maroto, M.; McLean, R.M.; Mustafa, R.A.; Tufte, J. Testosterone Treatment in Adult Men With Age-Related Low Testosterone: A Clinical Guideline From the American College of Physicians. Ann. Intern. Med.,  2020, 172(2), 126-133.
 [http://dx.doi.org/10.7326/M19-0882] [PMID:  31905405]

[3]
Sadosky, A. Kunal Srivastava; Anamika Arora; Aditi Kataria; Cappelleri; Peterson, A.M. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer. Adherence,  2013, 7, 419-434.
 [http://dx.doi.org/10.2147/PPA.S44646] [PMID:  23737662]

[4]
O’Neil, M. The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals; Royal Society of Chemistry, 2013. 

[5]
Thirumalai, A.; Rubinow, K.B.; Page, S.T. An update on testosterone, HDL and cardiovascular risk in men. Physiol. Behav.,  2017, 176(12), 139-148.
 [http://dx.doi.org/10.2217/clp.15.10.An]

[6]
Hadgraft, J.; Lane, M.E. Transdermal delivery of testosterone. Eur. J. Pharm. Biopharm.,  2015, 92, 42-48.
 [http://dx.doi.org/10.1016/j.ejpb.2015.02.015] [PMID:  25709060]

[7]
 Available from : https://www.rxlist.com/androderm-drug.htm
          (Accessed on: Dec 22, 2022).
      

[8]
Auxillium Pharmaceuticals Inc Testopel - Auxilium Pharmaceuticals, Inc.,, 2016. Available from : https://rxdruglabels.com/lib/rx/rx-meds/testopel/page/2/
             (Accessed on: 16 Jul 2020)
        

[9]
 Available from :   https://www.3m.com/3M/en_US/p/c/medical/tapes-films/transdermal/i/health-care/medical-device-components/?rt=comp&R=70000065055_en_US+70000200082_en_US
          (Accessed	on: 28 Jul 2021)
      

[10]
Samanidou, V.F.; Karageorgou, E.G.; Papadoyannis, I.N. Simultaneous determination of testosterone and its major metabolite epitestosterone in biological fluids by HPLC. J. Liq. Chromatogr. Relat. Technol.,  2007, 30(9-10), 1317-1331.
 [http://dx.doi.org/10.1080/10826070701274916]

[11]
Kupiec, T.C.; Skinner, R.; Lanier, L. Stability versus potency testing: The madness is in the method. Int. J. Pharm. Compd.,  2008, 12(1), 50-53.
 [PMID:  23969572]

[12]
Lloyd, R.; Snyder, L.R.; Kirkland, J.J.; Glajch, J.L. Method Validation Protocol. Practical HPLC Method Development, 2nd ed; John Wiley & Sons, 1997, p. 709.

[13]
Sheskey, P.J.; Hancock, B.C.; Moss, G.P.; Goldfarb, D.J. American Pharmacists Association, Handbook of pharmaceutical excipients, 9th ed; Pharmaceutical Press: London, 2021. 

[14]
 U.S. Pharmacopeial Convention. USP Monographs: Testosterone Topical Solution Monograph, Topical and Transdermal Drug Products- Product Quality Tests, Drug Release, and Pharmaceutical Dosage Forms. In: USP43-NF38.Pharmacopeia; Rockville MD:U.S; , 2022, pp. 4291-6415. 6957,7929

[15]
FDA Chloroform Toxicological overview. Gov.UK.  Available from :   https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/338535/Chloroform_Toxicological_Overview.pdf\
        	 (Accessed on: Dec 20, 2022)
        

[16]
]Testosterone Dissolution Database  Available from :  https://www.accessdata.fda.gov/scripts/cder/dissolution/dsp_SearchResults.cfm
        	 (Accessed on: 01 Aug 2022)
        

[17]
Kakade, A.  Dissolution Analyses: Comparison of Profiles Using f2	Analysis Calculation. EG Life Sciences.  Available from :  http://blog.eglifesciences.com/dissolution-analyses-comparison-of-profiles-using-f
           (Accessed on: 04 Jul 2022)
      

[18]
Shah, V.P.; Tsong, Y.; Sathe, P.; Williams, R.L. Dissolution profile comparison using similarity factor, f2. Dissolut. Technol.,  1999, 6(3), 15.
 [http://dx.doi.org/10.14227/DT060399P15]

[19]
Cleophas, T.J. Clinical trials and p-values, beware of the extremes. Clin. Chem. Lab. Med. (CCLM),  2004, 42(3), 300-304.
 [http://dx.doi.org/10.1515/CCLM.2004.054] [PMID: 15080563]

[20]
Stevenson, C.L.; Santini, J.T., Jr; Langer, R. Reservoir-based drug delivery systems utilizing microtechnology. Adv. Drug Deliv. Rev.,  2012, 64(14), 1590-1602.
 [http://dx.doi.org/10.1016/j.addr.2012.02.005] [PMID:  22465783]

[21]
Margetts, L.; Sawyer, R. Transdermal drug delivery: principles and opioid therapy. Contin. Educ. Anaesth. Crit. Care Pain,  2007, 7(5), 171-176.
 [http://dx.doi.org/10.1093/bjaceaccp/mkm033]

[22]
Dow Chemicals, C. Using METHOCEL Cellulose Ethers for Controlled Release of Drugs in Hydrophilic Matrix Systems. Matrix,  2019, E4148803.

[23]

Dermatological Preparations: Ointments and Pastes 2020 In: Applied	Pharmaceutics and Contemporary Compounding; Shrewsbury,;  R.Morton Publishing, 2020, pp. 222-223.

[24]

Topcial and Transdermal Formualtios Transdermal and Topical Drug Delivery from Theory to Clinical Practice; Williams, A., Ed.; Pharmaceutical Press: London, Chicago, 2003, pp. 178-186.

[25]
Stevens, R.E.; Gray, V.; Dorantes, A.; Gold, L.; Pham, L. Scientific and regulatory standards for assessing product performance using the similarity factor, f2. AAPS J.,  2015, 17(2), 301-306.
 [http://dx.doi.org/10.1208/s12248-015-9723-y] [PMID:  25669756]

[26]
Gong, X. Alternatives to f2 Testing for Dissolution Similarity - f2	Bootstrapping and MSD Method - YouTube.  2020. Available from :  https://www.youtube.com/watch?v=3tP_4OohHu4
          (Accessed on: 11	Jan 2022).
      

[27]
Mendyk, A. Pacławski, A.; Szlek, J.; Jachowicz, R. PhEq_bootstrap: Open-Source software for the simulation of f2 distribution in cases of large variability in dissolution profiles. Dissolut. Technol.,  2013, 20(1), 13-17.
 [http://dx.doi.org/10.14227/DT200113P13]

[28]
Zhang, Z.  FDA’s Current Practice and Challenges in the Use of DissolutionSimilarity Testing for Demonstration of Bioequivalence-Case	Studies, Office of Bioequivalence, Office of Generic Drugs. 2019. Available  from :   https://www.pharmacy.umaryland.edu/media/SOP/wwwpharmacyumarylandedu/centers/cersievents/dissolution-similarity/zhen-zhang-slides.pdf
          (Accessed on: 15 Aug 2022)
      

[29]
Taylor, K.M.G.; Aulton, M.E. Aulton’s Pharmaceutics: The design and manufacture of medicines, 6th ed; Elsevier, 2021, pp. 873-875.

Rights & Permissions Print Cite

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1567201820666230316115921	Print ISSN 1567-2018
Publisher Name Bentham Science Publisher	Online ISSN 1875-5704

Current Drug Delivery

Two Sustained Release Membranes Used in Formulating Low Strength Testosterone Reservoir Transdermal Patches

Abstract Play Pause

Graphical Abstract

Related Journals

Related Books

Abstract